Low muscle strength is an important heritable indicator of poor health linked to morbidity and mortality in older people. In a genome-wide association study meta-analysis of 256,523 Europeans aged 60 ...years and over from 22 cohorts we identify 15 loci associated with muscle weakness (European Working Group on Sarcopenia in Older People definition: n = 48,596 cases, 18.9% of total), including 12 loci not implicated in previous analyses of continuous measures of grip strength. Loci include genes reportedly involved in autoimmune disease (HLA-DQA1 p = 4 × 10
), arthritis (GDF5 p = 4 × 10
), cell cycle control and cancer protection, regulation of transcription, and others involved in the development and maintenance of the musculoskeletal system. Using Mendelian randomization we report possible overlapping causal pathways, including diabetes susceptibility, haematological parameters, and the immune system. We conclude that muscle weakness in older adults has distinct mechanisms from continuous strength, including several pathways considered to be hallmarks of ageing.
ABSTRACT
Introduction
The purpose of this study was to determine the impact of an in‐home expiratory muscle strength training (EMST) program on pulmonary, swallow, and cough function in individuals ...with amyotrophic lateral sclerosis (ALS).
Methods
EMST was tested in a prospective, single‐center, double‐blind, randomized, controlled trial of 48 ALS individuals who completed 8 weeks of either active EMST (n = 24) or sham EMST (n = 24). The primary outcome to assess treatment efficacy was change in maximum expiratory pressure (MEP). Secondary outcomes included: cough spirometry; swallowing; forced vital capacity; and scoring on the ALS Functional Rating Scale—Revised.
Results
Treatment was well tolerated with 96% of patients completing the protocol. Significant differences in group change scores were noted for MEP and Dynamic Imaging Grade of Swallowing Toxicity scores (P < 0.02). No differences were noted for other secondary measures.
Discussion
This respiratory training program was well‐tolerated and led to improvements in respiratory and bulbar function in ALS. Muscle Nerve 59:40–46, 2019
See editorial on pages 6–7 in this issue.
ABSTRACTFragala, MS, Cadore, EL, Dorgo, S, Izquierdo, M, Kraemer, WJ, Peterson, MD, and Ryan, ED. Resistance training for older adultsposition statement from the national strength and conditioning ...association. J Strength Cond Res XX(X)000–000, 2019—Aging, even in the absence of chronic disease, is associated with a variety of biological changes that can contribute to decreases in skeletal muscle mass, strength, and function. Such losses decrease physiologic resilience and increase vulnerability to catastrophic events. As such, strategies for both prevention and treatment are necessary for the health and well-being of older adults. The purpose of this Position Statement is to provide an overview of the current and relevant literature and provide evidence-based recommendations for resistance training for older adults. As presented in this Position Statement, current research has demonstrated that countering muscle disuse through resistance training is a powerful intervention to combat the loss of muscle strength and muscle mass, physiological vulnerability, and their debilitating consequences on physical functioning, mobility, independence, chronic disease management, psychological well-being, quality of life, and healthy life expectancy. This Position Statement provides evidence to support recommendations for successful resistance training in older adults related to 4 parts(a) program design variables, (b) physiological adaptations, (c) functional benefits, and (d) considerations for frailty, sarcopenia, and other chronic conditions. The goal of this Position Statement is to a) help foster a more unified and holistic approach to resistance training for older adults, b) promote the health and functional benefits of resistance training for older adults, and c) prevent or minimize fears and other barriers to implementation of resistance training programs for older adults.
We systemically reviewed the literature to assess how long-term testosterone suppressing gender-affirming hormone therapy influenced lean body mass (LBM), muscular area, muscular strength and ...haemoglobin (Hgb)/haematocrit (HCT).
Systematic review.
Four databases (BioMed Central, PubMed, Scopus and Web of Science) were searched in April 2020 for papers from 1999 to 2020.
Eligible studies were those that measured at least one of the variables of interest, included transwomen and were written in English.
Twenty-four studies were identified and reviewed. Transwomen experienced significant decreases in all parameters measured, with different time courses noted. After 4 months of hormone therapy, transwomen have Hgb/HCT levels equivalent to those of cisgender women. After 12 months of hormone therapy, significant decreases in measures of strength, LBM and muscle area are observed. The effects of longer duration therapy (36 months) in eliciting further decrements in these measures are unclear due to paucity of data. Notwithstanding, values for strength, LBM and muscle area in transwomen remain above those of cisgender women, even after 36 months of hormone therapy.
In transwomen, hormone therapy rapidly reduces Hgb to levels seen in cisgender women. In contrast, hormone therapy decreases strength, LBM and muscle area, yet values remain above that observed in cisgender women, even after 36 months. These findings suggest that strength may be well preserved in transwomen during the first 3 years of hormone therapy.
...as pointed out by the authors, the current study indeed lacks assessment measures related to exercise performance. ...the prioritization of muscle stiffness indices using shear wave elastography ...was paramount, while the selected measures, such as internal and external rotation range of motion and muscle strength of the shoulder joint, which are believed to be related to muscle stiffness, were based on this objective. ...since none of the subjects in this study were smokers and none of the swimmers consumed alcohol daily, it is unlikely that unhealthy lifestyle habits such as smoking and excessive drinking contributed to swimmer's shoulder pain in our cohort study. ...given that a relationship between sleep duration and injury occurrence in athletes has been reported,5,6 it is important to consider the lifestyle habits noted by the authors and further examine them in athlete populations.
Abstract
Objective
This study aimed to evaluate the intrarater and interrater reliability of isometric quadriceps strength (IQS) using a portable dynamometer in individuals with chronic obstructive ...pulmonary disease (COPD) and to verify their tolerance to the protocol.
Methods
A cross-sectional reliability study was conducted with 50 individuals with stable COPD (34 men and 16 women; mean age = 70 years SD = 8). The main outcome measure was obtained using a portable dynamometer (Microfet 2) to assess IQS. Two masked raters performed 2 assessments in the dominant lower limb on 2 nonconsecutive days. The intraclass correlation coefficient (ICC) was used to verify the intrarater and interrater reliability and was considered excellent when >0.90, with a 5% significance level.
Results
Rater 1 and 2 intrarater reliability was as follows: ICC = 0.96 (95% CI = 0.94 to 0.98) and ICC = 0.97 (95% CI = 0.95 to 0.98), respectively. The interrater reliability was as follows: ICC = 0.96 (95% CI = 0.93 to 0.98). The minimum detectable difference was 4 to 5 peak isometric strength, in mean, for intrarater and interrater reliability. Not all patients presented relevant changes in physiological responses, dyspnea, and lower limb fatigue.
Conclusion
There was an excellent intrarater and interrater reliability for IQS, and the participants tolerated the protocol.
Impact
This tool can be used to assess quadriceps strength in clinical practice in patients with COPD.
Context:
Testosterone's effects on muscle strength and physical function in older men have been inconsistent; its effects on muscle power and fatigability have not been studied.
Objective:
To ...determine the effects of testosterone administration for 3 years in older men on muscle strength, power, fatigability and physical function
Study Design:
In this double-blind, placebo-controlled, randomized trial, healthy men ≥60 years with total testosterone 100–400 ng/dL or free testosterone <50 pg/mL, were randomized to 7.5-g 1% testosterone or placebo gel daily for 3 years.
Outcomes:
Loaded and unloaded stair-climbing power, muscle strength, power, and fatigability in leg press and chest press exercises, and lean mass at baseline, 6, 18, and 36 months.
Results:
The groups were similar at baseline. Testosterone administration for 3 years was associated with significantly greater performance in unloaded and loaded stair-climbing power than placebo (mean (95% CI) estimated between-group difference 10.7W (-4.0,25.5; P=0.026) and 22.4W (4.6,40.3) P=0.027), respectively. Changes in chest press strength (estimated mean difference 16.3N (95% CI 5.5,27.1; P<0.001) and power (mean (95%CI) difference 22.5W (7.5,37.5); P<0.001), and leg press power were significantly greater in men randomized to testosterone than in those randomized to placebo. Lean body mass significantly increased more in the testosterone group.
Conclusion:
Compared to placebo, testosterone replacement in older men for 3 years was associated with modest but significantly greater improvements in stair-climbing power, muscle mass and power. Clinical meaningfulness of these treatment effects and their impact on disability in older adults with functional limitations remains to be studied.
Key points
Recent evidence suggests that impaired mitophagy, a process in charge of removing damaged/dysfunctional mitochondria and in part regulated by Parkin, could contribute to the ageing‐related ...loss of muscle mass and function.
In the present study, we show that Parkin overexpression attenuates ageing‐related loss of muscle mass and strength and unexpectedly causes hypertrophy in adult skeletal muscles. We also show that Parkin overexpression leads to increases in mitochondrial content and enzymatic activities. Finally, our results show that Parkin overexpression protects from ageing‐related increases in markers of oxidative stress, fibrosis and apoptosis.
Our findings place Parkin as a potential therapeutic target to attenuate sarcopenia and improve skeletal muscle health and performance.
The ageing‐related loss of muscle mass and strength, a process called sarcopenia, is one of the most deleterious hallmarks of ageing. Solid experimental evidence indicates that mitochondrial dysfunctions accumulate with ageing and are critical in the sarcopenic process. Recent findings suggest that mitophagy, the process in charge of the removal of damaged/dysfunctional mitochondria, is altered in aged muscle. Impaired mitophagy represents an attractive mechanism that could contribute to the accumulation of mitochondrial dysfunctions and sarcopenia. To test this hypothesis, we investigated the impact of Parkin overexpression in skeletal muscles of young and old mice. Parkin was overexpressed for 4 months in muscles of young (3 months) and late middle‐aged (18 months) mice using i.m. injections of adeno‐associated viruses. We show that Parkin overexpression increased muscle mass, fibre size and mitochondrial enzyme activities in both young and old muscles. In old mice, Parkin overexpression increased muscle strength, primordial germ cell‐1α content and mitochondrial density. Parkin overexpression also attenuated the ageing‐related increase in 4‐hydroxynonenal content (a marker of oxidative stress) and type I collagen content (a marker of fibrosis), as well as the number of terminal deoxynucleotidyl transferase dUTP nick‐end labelling‐positive myonuclei (a marker of apoptosis). Overall, our results indicate that Parkin overexpression attenuates sarcopenia and unexpectedly causes hypertrophy in adult muscles. They also show that Parkin overexpression leads to increases in mitochondrial content and enzymatic activities. Finally, our results show that Parkin overexpression protects against oxidative stress, fibrosis and apoptosis. These findings highlight that Parkin may be an attractive therapeutic target with respect to attenuating sarcopenia and improving skeletal muscle health and performance.
Key points
Recent evidence suggests that impaired mitophagy, a process in charge of removing damaged/dysfunctional mitochondria and in part regulated by Parkin, could contribute to the ageing‐related loss of muscle mass and function.
In the present study, we show that Parkin overexpression attenuates ageing‐related loss of muscle mass and strength and unexpectedly causes hypertrophy in adult skeletal muscles. We also show that Parkin overexpression leads to increases in mitochondrial content and enzymatic activities. Finally, our results show that Parkin overexpression protects from ageing‐related increases in markers of oxidative stress, fibrosis and apoptosis.
Our findings place Parkin as a potential therapeutic target to attenuate sarcopenia and improve skeletal muscle health and performance.
Many studies have investigated the relationship between hypertension and its association with muscle health, showing controversial results on the subject. It is believed that high blood pressure can ...reduce the blood supply and cause damage to the arteries that supply areas of the motor cortex, responsible for muscle contraction and mobility, leading to a decay of functionality and reduced oxygen consumption and muscle strength. However, during aging there is a natural decrease in muscle mass, strength and quality, associated with the process of sarcopenia, although there are still difficulties identifying which factors are responsible for causing and worsening this process. In this context, it is believed that hypertension may play an important role in understanding this issue.
compare isokinetic muscle function, muscle mass and gait speed among normotensive and hypertensive older adults.
A cross-sectional observational study was conducted with 81 community-dwelling older adults selected by convenience. Participants were older people capable of walking without assistance and without cognitive alterations detectable by the Mini-Mental State Examination (MMSE). The diagnosis of arterial hypertension (independent variable) was made through the self-report of the participant´s previous medical diagnosis of arterial hypertension, validated by the record of using antihypertensive medication. The dependent variables of the study were: peak torque, muscle power, work by body weight and agonist-antagonist ratio of hip, knee and ankle (isokinetic dynamometry), handgrip strength (handgrip dynamometry), muscle mass (calf circumference) and usual gait speed at 10 meters. The dependent variables were compared between the groups of normotensive and hypertensive older adults by means of simple analyses and covariance adjusted for sex.
most participants were female (51.9%), active (53.1%) and hypertensive (74%). In the simple analyses, it was observed that the hypertensive older group presented lower handgrip strength, lower mean peak torque of hip extensors and knee flexors, lower muscle power of knee flexors and extensors, lower work by body weight of hip flexors and knee extensors and lower knee agonist-antagonist ratio. However, in the analysis of covariance adjusted for sex, only in the knee agonist-antagonist ratio was found a statistically significant difference between the groups (40.64±9.01 vs 45.78±7.34; p=0.040).
The study identified a lower knee agonist-antagonist ratio in hypertensive older adults when compared to normotensive patients. Our findings are linked to changes in muscle functioning that reflect uncoordinated activation of knee agonists and antagonists, although such changes cannot be fully explained by a significant reduction in strength.
The understanding of hypertension and its impacts on muscle health contributes to a better understanding of the factors that cause and worsen the decline of muscle function in the older adults, in addition to being a potential contributor to the planning of health care strategies for the older people with a focus on the prevention and correct prescription of physical exercises.